340 related articles for article (PubMed ID: 32899464)
1. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma.
Cronk RJ; Zurko J; Shah NN
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899464
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
Front Immunol; 2019; 10():1613. PubMed ID: 31379824
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
5. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
[TBL] [Abstract][Full Text] [Related]
7. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
[TBL] [Abstract][Full Text] [Related]
8. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
9. Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies.
Xie B; Li Z; Zhou J; Wang W
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805001
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
11. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
Qin H; Ramakrishna S; Nguyen S; Fountaine TJ; Ponduri A; Stetler-Stevenson M; Yuan CM; Haso W; Shern JF; Shah NN; Fry TJ
Mol Ther Oncolytics; 2018 Dec; 11():127-137. PubMed ID: 30581986
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
15. [Clinical development of CAR-T therapy for refractory multiple myeloma].
Ohmine K
Rinsho Ketsueki; 2018; 59(8):1058-1065. PubMed ID: 30185706
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
17. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy for multiple myeloma.
Hosen N
Int J Hematol; 2020 Apr; 111(4):530-534. PubMed ID: 31981097
[TBL] [Abstract][Full Text] [Related]
19. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.
Qiu L; Zhu F; Wei G; Wu W; Yang L; Hu Y; Huang H
Regen Ther; 2020 Jun; 14():271-274. PubMed ID: 32455157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
